在使用抗纤维化策略的抗衰老治疗中新兴的前景
Yu Wang1,2, Chenshi Xi1, Jiangli Yang1
1Brain and Cognition Research Institute, School of Medicine, Hangzhou City University, Hangzhou 310015, China.
Aging and disease
|October 24, 2025
概括
老龄化导致器官退化和纤维化,与癌症有关. 用传统中医和基因疗法等疗法向纤维化提供了新的抗衰老和抗癌策略.
科学领域:
- 生物医学科学 生物医学科学
- 老年学是一门学科.
- 在瘤学瘤学.
背景情况:
- 衰老导致慢性器官退化,细胞再生减少和细胞外基质 (ECM) 积累,导致器官纤维化,这是器官衰竭的标志.
- 纤维化和衰老共享重叠的分子机制,与年龄相关的炎症和受损的再生促进纤维细胞激活和ECM积累.
- 瘤微环境表现出脱质形成 (过度的ECM),支持癌症生长,突出了纤维化和恶性瘤之间的联系.
研究的目的:
- 审查关键细胞类型和器官衰老和纤维化中的分子途径.
- 突出抗纤维化传统中医药 (TCM) 和癌症和衰老的基因/细胞疗法的进展.
- 探索新兴技术,如纳米医学和有机体在抗纤维性药物开发中的作用.
主要方法:
- 关于衰老,纤维化,癌症和治疗策略的文献综述.
- 分析分子通路和细胞类型,涉及纤维化的进展.
- 检查药物发现的新技术方法.
主要成果:
- 衰老和纤维化有共同的细胞和分子路径,特别是涉及纤维细胞.
- 与癌症相关的纤维细胞在瘤进展和纤维化发育中起着关键作用.
- 传统中国医学 (TCM),基因疗法,细胞疗法,纳米医学和有机体模型显示出抗纤维和抗衰老治疗的前景.
结论:
- 了解衰老,纤维化和癌症之间的相互作用,特别是纤维细胞的作用,对于开发新疗法至关重要.
- 整合分子医学,TCM和先进技术为抗纤维菌药物发现和治疗开发提供了一个强大的框架.
- 新兴技术对于推进针对衰老和癌症的抗纤维菌疗法至关重要.
相关概念视频
01:19The Effect of Aging on Tissues
3.3K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
3.3K
01:26Aging
587
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
587
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
01:30Heart Failure V: Medical Management
215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
01:22Heart Failure VI: Adjunct Therapies
252
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
252